Pharmaceutical company Mesoestetic has launched the mesofiller periocular, a new cross-linked HA dermal filler.
The company explains that the product contains 15 mg/ml of fully cross-linked hyaluronic acid which is designed to give a softer filling, greater adaptability to high-gesticulation areas and can be used for correcting the frontal and periocular area.
Mesoestetic performed a clinical study on 16 volunteers for rejuvenation of the periocular area, which they state showed a 100% improvement of the patients and achieved a long lasting result after 12 months. The company noted that treatment safety was evaluated immediately after treatment and after 100 days, with only local, mild and transient skin effects.
According to mesoestetic, the mesofiller range is developed using densiMatrix technology, which binds HA molecules by BDDE, has a process to remove the unused BDDE that did not react and measure its residual concentration, and creates gel fractionation into particles.
